Interventions for Tuberculosis Control and Elimination 2002

1095. Yang B, Koga H, Ohno H, Ogawa K, Fukuda M, Hirakata Y, Maesaki S,
Tomono K, Tashiro T, Kohno S. Relationship between antimycobacterial activities
of rifampicin, rifabutin and KRM-1648 and rpoB mutations of
Mycobacterium tuberculosis. J Antimicrob Chemother 1998; 42: 621-8.
1096. Sintchenko V, Chew WK, Jelfs PJ, Gilbert GL. Mutations in the rpoB gene
and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis
strains isolated in Australia. Pathology 1999; 31: 257-60.
1097. Arioli V, Berti M, Carniti G, Randisi E, Rossi E, Scotti R. Antibacterial activity
of DL 473, a new semisynthetic rifamycin derivative.
24: 1026-32.
J Antibiotics 1981;
1098. Dickinson JM, Mitchison DA. In vitro properties of rifapentine (MDL 473)
relevant to its use in intermittent chemotherapy of tuberculosis.
68: 113-8.
Tubercle 1987;
1099. Jarvis B, Lamb HM. Rifapentine. Drugs 1998; 56: 607-16.
1100. Miyazaki E, Chaisson RE, Bishai WR. Analysis of rifapentine for preventive
therapy in the Cornell mouse model of latent tuberculosis.
Chemother 1999; 43: 2126-30.
Antimicrob Agents
1101. Grosset J, Lounis N, Truffot-Pernot C, O’Brien RJ, Raviglione MC, Ji B. Onceweekly
rifapentine-containing regimens for treatment of tuberculosis in mice.
Am J Respir Crit Care Med 1998; 157: 1436-40.
1102. Keung ACF, Owens RC, Jr., Eller MG, Weir SJ, Nicolau DP, Nightingale CH.
Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency
virus: a phase I study.
1230-3.
Antimicrob Agents Chemother 1999; 43:
1103. Reith K, Keung A, Toren PC, Cheng L, Eller MG, Weir SJ. Disposition and
metabolism of 14C-rifapentine in health volunteers.
26: 732-8.
Drug Metabolism Disp 1998;
1104. Marshall JD, Abdel-Rahman S, Johnson K, Kauffman RE, Kearns GL.
Rifapentine pharmacokinetics in adolescents.
882-8.
Pediatr Infect Dis J 1999; 18:
1105. Conte JE, Jr., Golden JA, McQuitty M, Kipps J, Lin ET, Zurlinden E. Singledose
intrapulmonary pharmacokinetics of rifapentine in normal subjects.
Antimicrob Agents Chemother 2000; 44: 985-90.
1106. Gardner TS, Wenis E, Lee J. The synthesis of compounds for the chemotherapy
of tuberculosis. IV. The amide function. J Org Chemistry 1954; 19: 753-7.
1107. Libermann D, Moyeux M, Rist N, Grumbach F. Sur la préparation de nouveaux
thioamides pyridiniques actifs dans la tuberculose expérimentale.
Acad Sci Paris 1956; 242: 2409-12.
C R
1108. Rist N, Grumbach F, Libermann D. Experiments on the antituberculous activity
of alpha-ethyl-thioisonicotinamide. Am Rev Respir Dis 1959; 79: 1-5.
243